Intranasal treatment against COVID-19

This technology is an intranasal treatment that can protect against COVID-19 and its variants.

Unmet Need: Broad protection against COVID-19 and its viral variants

Current methods to prevent the spread of SARS-CoV-2 rely on life-saving vaccines and medications, but as the virus continues to rapidly mutate, vaccinesefficacy decreases. Although additional viral load injections can improve immune defense, there is currently no easy-to-use treatment activating the immune system locally.

The Technology: Intranasal injection for broad protection against COVID-19 and other respiratory viruses

This technology is an intranasal injection which activates an immune defense specifically in the nasal cavity. A glyolipid is delivered intranasally to activate T cells, which in turn activate other immune cells and secrete anti-viral cytokines. Through this cascade, the immune system can develop anti-viral properties in the nasal cavity and show prophylactic protection against SARS-CoV-2 infection. This treatment can improve outcomes following COVID-19 but also for other respiratory viruses’ infections.

This technology has been validated with mice.

Applications:

  • Treatment for COVID-19
  • Treatment for other viral respiratory infections
  • Research tool to study T cell activation
  • Prophylactic use by medical professionals and essential workers
  • Adjuvant to increase the efficacy of existing vaccines

Advantages:

  • Broad protection against all SARS-CoV-2 variants and all respiratory viral infections
  • Easy administration
  • No virus-induced side effects

Lead Inventor:

Moriya Tsuji, Ph.D.

Patent Information:

Patent Pending

Related Publications:

Tech Ventures Reference: